The growing incidence of migraine is anticipated to accelerate the demand for treatment options globally. Headache results for 4.4% of all general practice visits, almost 5% of all medical hospital admissions, and more than 20% of neurology outpatient consultations. Also, the frequency of migraines in females is seen to increase at the time of post-pubertal ages than males. Migraine affects around 20% of people at some point in their lives. The global studies state that around 1% of the world's population suffers from chronic migraine.
Data Bridge Market Research analyses that the Global Migraine Treatment Market which was USD 2.38 billion in 2021, is expected to reach USD 4.67 billion by 2029, and is expected to undergo a CAGR of 8.80% during the forecast period 2022 to 2029. The increasing demand for the migraine treatment will provide potential opportunities for the market growth in the forecast period.
Increasing female population is anticipated to drive the market's growth rate
Migraine is known to be more widespread in female compared to male. The frequency of developing migraine in females rises at the time of post-pubertal ages compared to males. The reduction in the female feticide's in developed and developing countries tends to increase the female ratio globally. The increased female population is proportionally increasing the migraine treatment market.
For instance,
- As per the study reported in a review article by American Headache Society in the year 2018 on "one year study done by Lipton RB et al on the prevalence of migraine among male and female", it was concluded that nearly 75% of females are more susceptible to migraine than only 25% of males
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/ Prophylactic Treatment, Non-Pharmacological Therapies and Devices), Route of Administration (Oral, Parenteral, Nasal Sprays and Others), Product Type (Prescription and Over The Counter), Type (Branded and Generic), End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies And Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S), Lilly (U.S), Amgen Inc. (U.S), GSK plc. (U.K), Novartis AG (Switzerland), Bayer AG (Germany), Abbvie, Inc (U.S.), Abbott (U.S), Allodynic Therapeutics, LLC (U.S), AOBiome (U.S), AstraZeneca (U.K), Aurobindo Pharma USA (U.S), Bausch Health Companies Inc. (Canada), Biohaven Pharmaceuticals (U.S), Boehringer Ingelheim International GmbH (Germany), Catalent, Inc (U.S), Dr. Reddy's Laboratories Ltd. (India), Impel Pharmaceuticals Inc. (U.S), H. Lundbeck A/S (Denmark), Merck & Co., Inc (U.S)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand
|
Segment Analysis:
Global migraine treatment market is categorized into seven notable segments on the basis of types, treatment, route of administration, product type, type, end-user and distribution channel.
- On the basis of types, the market is segmented into episodic, chronic, migraine with aura and others.
The episodic segment of types is anticipated to dominate the migraine treatment market
The episodic segment is expected to dominate the market with 53.63% market share as it is the most widespread form of migraine typically characterized by 0 to 14 headache days per month.
- On the basis of treatment, the market is segmented into acute/abortive treatment, preventive/prophylactic treatment, non-pharmacological therapies and devices.
The acute/abortive treatment segment of treatment type is anticipated to dominate the migraine treatment market
The acute/abortive treatment is expected to dominate the market with 55.07% market share because of the advancement in therapies over the past years than preventive/prophylactic treatment, non-pharmacological therapies and devices which have gained much attention in relatively last few years.
- On the basis of route of administration, the market is segmented into oral, parenteral, injectable, nasal sprays and others. The oral segment is expected to dominate the market with 81.14% market share as most of the drugs including the first line therapy drugs for acute/abortive treatment and prophylactic treatment are widely available in the oral form with highest effectiveness.
- On the basis of product type, the market is segmented into prescription and over the counter. The prescription segment is expected to dominate the market with 77.79% market share market as the majority of migraine treatment drugs including CGRP antagonists, triptans, Beta-blockers, ergotamines, calcium channel blockers and others are available on the prescription basis.
- On the basis of type, the market is segmented into branded and generic. The generic segment is expected to dominate the market with 74.48% market share as migraine treatment is a well-established market, maximum branded drugs have expired and few new treatments are readily available as branded drugs.
- On the basis of end user, the market is segmented into hospitals, clinics, homecare and others. The hospitals segment is expected to dominate the global market with 49.42% market share because of the high degree of disability caused by migraine.
- On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. The hospital pharmacies segment is expected to dominate the global market with 57.00% market share as hospitals are the main source of procurement of drugs by patients.
Major Players
Data Bridge Market Research recognizes the following companies as the major migraine treatment market players in migraine treatment market are Pfizer Inc. (U.S), Lilly (U.S), Amgen Inc. (U.S), GSK plc. (U.K), Novartis AG (Switzerland), Bayer AG (Germany), Abbvie, Inc (U.S.), Abbott (U.S), Allodynic Therapeutics, LLC (U.S), AOBiome (U.S), AstraZeneca (U.K), Aurobindo Pharma USA (U.S), Bausch Health Companies Inc. (Canada), Biohaven Pharmaceuticals (U.S), Boehringer Ingelheim International GmbH (Germany), Catalent, Inc (U.S), Dr. Reddy's Laboratories Ltd. (India), Impel Pharmaceuticals Inc. (U.S), H. Lundbeck A/S (Denmark), Merck & Co., Inc (U.S).
Market Development
- In 2022, FDA approved Elyxyb (celecoxib oral solution) is a novel fast-acting liquid from BioDelivery Sciences. It's one of the first FDA-approved ready-to-use oral treatments for individuals suffering from acute migraine with or without aura.
- In 2019, the FDA approved lasmiditan (REYVOW) for the treatment of migraine pain in adults. It is administered orally as a pill and acts on both migraines (with or without aura). REYVOW is the first migraine treatment in a class of serotonin (5-HT) 1F receptor agonist's drugs.
- In 2019, the U.S. Food and Drug Administration approved the first oral drug in the class of calcitonin gene-related peptide receptor antagonists called Ubrelvy (ubrogepant) for the immediate treatment of migraine with or without aura in adults.
Regional Analysis
Geographically, the countries covered in the migraine treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in migraine treatment market during the forecast period 2022 to 2029
North America dominates the migraine treatment market as it is the largest consumer of pharmaceuticals. This region will continue to dominate the market due to the high capital investments and increasing adoption of advanced technology and launch of several new products in this region. Furthermore, the launch of several novel drugs in this region makes it an important market for branded drugs.
Asia-Pacific is estimated to be the fastest-growing region in migraine treatment market the forecast period 2022 to 2029
Asia-Pacific is expected to grow during the forecast period of 2022 to 2029 because of the increased awareness associated with migraine due to the growing migraine cases across hospitals and clinics in this region. Additionally, increasing healthcare expenditure and high number of investors and new market players are anticipated to boost the market's growth rate in this region.
For more detailed information about migraine treatment market report, click here – https://www.databridgemarketresearch.com/ar/reports/global-migraine-treatment-market
